TY - JOUR
T1 - Mechanical Thrombectomy Versus Intravenous Thrombolysis in Distal Medium Vessel Acute Ischemic Stroke
T2 - A Multinational Multicenter Propensity Score-Matched Study
AU - Salim, Hamza Adel
AU - Yedavalli, Vivek
AU - Musmar, Basel
AU - Adeeb, Nimer
AU - Essibayi, Muhammed Amir
AU - Naamani, Kareem El
AU - Henninger, Nils
AU - Sundararajan, Sri Hari
AU - Kühn, Anna Luisa
AU - Khalife, Jane
AU - Ghozy, Sherief
AU - Scarcia, Luca
AU - Tan, Benjamin Y Q
AU - Pulli, Benjamin
AU - Heit, Jeremy J
AU - Regenhardt, Robert W
AU - Cancelliere, Nicole M
AU - Bernstock, Joshua D
AU - Rouchaud, Aymeric
AU - Fiehler, Jens
AU - Sheth, Sunil
AU - Puri, Ajit S
AU - Dyzmann, Christian
AU - Colasurdo, Marco
AU - Barreau, Xavier
AU - Renieri, Leonardo
AU - Filipe, João Pedro
AU - Harker, Pablo
AU - Radu, Razvan Alexandru
AU - Marotta, Thomas R
AU - Spears, Julian
AU - Ota, Takahiro
AU - Mowla, Ashkan
AU - Jabbour, Pascal
AU - Biswas, Arundhati
AU - Clarençon, Frédéric
AU - Siegler, James E
AU - Nguyen, Thanh N
AU - Varela, Ricardo
AU - Baker, Amanda
AU - Altschul, David
AU - Gonzalez, Nestor R
AU - Möhlenbruch, Markus A
AU - Costalat, Vincent
AU - Gory, Benjamin
AU - Stracke, Christian Paul
AU - Aziz-Sultan, Mohammad Ali
AU - Hecker, Constantin
AU - Shaikh, Hamza
AU - Liebeskind, David S
AU - MAD MT Investigators
N1 - Hecker: Departments of Neurology & Neurosurgery, Christian Doppler Clinic, Paracelsus Medical University, Salzburg, Austria
PY - 2024/9
Y1 - 2024/9
N2 - BACKGROUND AND PURPOSE: The management of acute ischemic stroke (AIS) due to distal medium vessel occlusion (DMVO) remains uncertain, particularly in comparing the effectiveness of intravenous thrombolysis (IVT) plus mechanical thrombectomy (MT) versus IVT alone. This study aimed to evaluate the safety and efficacy in DMVO patients treated with either MT-IVT or IVT alone.METHODS: This multinational study analyzed data from 37 centers across North America, Asia, and Europe. Patients with AIS due to DMVO were included, with data collected from September 2017 to July 2023. The primary outcome was functional independence, with secondary outcomes including mortality and safety measures such as types of intracerebral hemorrhage.RESULTS: The study involved 1,057 patients before matching, and 640 patients post-matching. Functional outcomes at 90 days showed no significant difference between groups in achieving good functional recovery (modified Rankin Scale 0-1 and 0-2), with adjusted odds ratios (OR) of 1.21 (95% confidence interval [CI] 0.81 to 1.79; P=0.35) and 1.00 (95% CI 0.66 to 1.51; P>0.99), respectively. Mortality rates at 90 days were similar between the two groups (OR 0.75, 95% CI 0.44 to 1.29; P=0.30). The incidence of symptomatic intracerebral hemorrhage was comparable, but any type of intracranial hemorrhage was significantly higher in the MT-IVT group (OR 0.43, 95% CI 0.29 to 0.63; P<0.001).CONCLUSION: The results of this study indicate that while MT-IVT and IVT alone show similar functional and mortality outcomes in DMVO patients, MT-IVT presents a higher risk of hemorrhagic complications, thus MT-IVT may not routinely offer additional benefits over IVT alone for all DMVO stroke patients. Further prospective randomized trials are needed to identify patient subgroups most likely to benefit from MT-IVT treatment in DMVO.
AB - BACKGROUND AND PURPOSE: The management of acute ischemic stroke (AIS) due to distal medium vessel occlusion (DMVO) remains uncertain, particularly in comparing the effectiveness of intravenous thrombolysis (IVT) plus mechanical thrombectomy (MT) versus IVT alone. This study aimed to evaluate the safety and efficacy in DMVO patients treated with either MT-IVT or IVT alone.METHODS: This multinational study analyzed data from 37 centers across North America, Asia, and Europe. Patients with AIS due to DMVO were included, with data collected from September 2017 to July 2023. The primary outcome was functional independence, with secondary outcomes including mortality and safety measures such as types of intracerebral hemorrhage.RESULTS: The study involved 1,057 patients before matching, and 640 patients post-matching. Functional outcomes at 90 days showed no significant difference between groups in achieving good functional recovery (modified Rankin Scale 0-1 and 0-2), with adjusted odds ratios (OR) of 1.21 (95% confidence interval [CI] 0.81 to 1.79; P=0.35) and 1.00 (95% CI 0.66 to 1.51; P>0.99), respectively. Mortality rates at 90 days were similar between the two groups (OR 0.75, 95% CI 0.44 to 1.29; P=0.30). The incidence of symptomatic intracerebral hemorrhage was comparable, but any type of intracranial hemorrhage was significantly higher in the MT-IVT group (OR 0.43, 95% CI 0.29 to 0.63; P<0.001).CONCLUSION: The results of this study indicate that while MT-IVT and IVT alone show similar functional and mortality outcomes in DMVO patients, MT-IVT presents a higher risk of hemorrhagic complications, thus MT-IVT may not routinely offer additional benefits over IVT alone for all DMVO stroke patients. Further prospective randomized trials are needed to identify patient subgroups most likely to benefit from MT-IVT treatment in DMVO.
U2 - 10.5853/jos.2024.01389
DO - 10.5853/jos.2024.01389
M3 - Original Article
C2 - 39266014
SN - 2287-6391
VL - 26
SP - 434
EP - 445
JO - JOURNAL OF STROKE
JF - JOURNAL OF STROKE
IS - 3
ER -